Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

(iii)     Each Party acknowledges and agrees that (a) Section ‎2.7.1 has been negotiated by the Parties, (b) the geographical and time limitations on activities set forth in this Section ‎2.7.1 are reasonable, valid and necessary in light of the Parties’ circumstances and necessary for the adequate protection of the business of the Licensed Compounds and the Licensed Products and (c) the other Party would not have entered into this Agreement without the protection afforded it by this Section ‎2.7.1. If, notwithstanding the foregoing, a court of competent jurisdiction determines that the restrictions set forth in this Section ‎2.7.1 are too broad or otherwise unreasonable under Applicable Law, including with respect to duration, geographic scope or space, the court is hereby requested and authorized by the Parties to revise this Section ‎2.7.1 to include the maximum restrictions allowable under Applicable Law.

 

2.7.2.       Change of Control of ACI. [*****].

 

ARTICLE 3
DEVELOPMENT AND REGULATORY ACTIVITIES

 

3.1.       Development.

 

3.1.1.       In General. Except as provided in Section ‎3.1.2 and Section ‎3.2, as between the Parties, from and after the Effective Date, Lilly shall have the sole right and responsibility, at its sole cost and expense, for all aspects of the Development of each Licensed Compound and Licensed Product. Without limiting the generality of the foregoing, from and after the Effective Date, except as provided in Section ‎3.2, Lilly shall have the sole right and responsibility, at its sole cost and expense, to (i) file all Drug Approval Applications and make all other filings with the Regulatory Authorities, and to otherwise seek all Regulatory Approvals for Licensed Products, in the Territory, as well as to conduct all correspondence and communications with Regulatory Authorities regarding such matters and (ii) report all Adverse Events to Regulatory Authorities if and to the extent required by Applicable Law.

 

3.1.2.       Joint Development.

 

(i)       Attached hereto as Schedule 3.1.2(i) is the initial plan for the Development of the Licensed Product (the “Development Plan”) in the First Indication and Second Indication, which plan shall assign responsibility for Development activities between the Parties (such activities, “Joint Development Activities”).

 

23 


© AC Immune 2015